Minimal change disease diagnostic study of choice

Jump to navigation Jump to search

Minimal Change Disease Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Minimal Change Disease from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Immunohistology

Electron Microscopy

Electrocardiogram

X-ray

Echocardiorgaphy or Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Minimal change disease diagnostic study of choice On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Minimal change disease diagnostic study of choice

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Minimal change disease diagnostic study of choice

CDC on Minimal change disease diagnostic study of choice

Minimal change disease diagnostic study of choice in the news

Blogs on Minimal change disease diagnostic study of choice

Directions to Hospitals Treating Minimal change disease

Risk calculators and risk factors for Minimal change disease diagnostic study of choice

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vamsikrishna Gunnam M.B.B.S [2]

Overview

The diagnostic study of choice for minimal change disease is renal biopsy.

Diagnostic Study of choice

  • The diagnostic study of choice for minimal change disease is renal biopsy.[1]
  • With four weeks of treatment with steroid therapy, most of the patients with minimal change disease (MCD) will respond positively.
  • Before considering renal biopsy steroid therapy can be initiated in patients who fulfill the following criteria because of the invasive process of the biopsy.[2][3]
  • Patients must be older than 1 year and less than 12 years.
  • Normal complement levels.
  • No signs of hypertension, gross hematuria, or a marked increase in serum creatinine.
  • By following this protocol in patients with minimal change disease we can avoid unnecessary invasive approach in almost 80% of the patients.[4]

References

  1. Vivarelli M, Massella L, Ruggiero B, Emma F (February 2017). "Minimal Change Disease". Clin J Am Soc Nephrol. 12 (2): 332–345. doi:10.2215/CJN.05000516. PMC 5293332. PMID 27940460.
  2. "The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. A report of the International Study of Kidney Disease in Children". J. Pediatr. 98 (4): 561–4. April 1981. PMID 7205481.
  3. Norero C, Delucchi A, Lagos E, Rosati P (May 1996). "[Initial therapy of primary nephrotic syndrome in children: evaluation in a period of 18 months of two prednisone treatment schedules. Chilean Co-operative Group of Study of Nephrotic Syndrome in Children]". Rev Med Chil (in Spanish; Castilian). 124 (5): 567–72. PMID 9035508.
  4. "The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. A report of the International Study of Kidney Disease in Children". J. Pediatr. 98 (4): 561–4. April 1981. PMID 7205481.